Busulfan 6 mg/ml concentrate for solution for infusion clinical trials

AAA-IPC 2011-003 - Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditioning of allogeneic stem cell transplantation (SCT) from a matched related or unrelated donor in patients with poor prognosis myeloïd malignancies

This study looks at different doses of chemotherapy drugs to treat serious blood cancers. It aims to see how long patients live without their cancer getting worse after a stem cell transplant from a donor.